StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
10
This year
1
Publishing Date
2024 - 01 - 09
1
2022 - 11 - 28
1
2022 - 11 - 03
1
2022 - 08 - 12
1
2022 - 01 - 07
1
2021 - 11 - 09
1
2021 - 07 - 01
1
2021 - 01 - 25
1
2021 - 01 - 19
1
2020 - 12 - 04
1
Sector
Health technology
10
Tags
Agreement
1
Application
1
Arcus
1
Bio-nc
3
Biotechnology
1
Cancer
1
Car-t
5
Cd19
2
Cel
1
Cell
1
Commercialization
1
Fda
1
Fda acceptance
1
Funding
1
Global
2
Immunotherapy
1
Leukemia
1
License
1
Market
1
Meeting
1
N/a
6
Patent
1
Pbcar0191
2
Phase 1
2
Phase 2
1
Phase 3
1
Positive
1
Presentation
1
Program
1
Report
1
Results
1
T-cell
4
Therapeutics
1
Therapy
3
Treatment
1
Trial
2
Entities
Abbvie inc.
6
Abcellera biologics inc
7
Achilles therapeutics plc - adr
6
Adaptive biotechnologies corporation
5
Adc therapeutics sa
5
Adicet bio, inc.
9
Allogene therapeutics, inc.
16
Allovir, inc.
4
Anaptysbio, inc.
4
Arcellx, inc.
4
Autolus therapeutics plc
15
Bellicum pharmaceuticals, inc.
5
Biontech se
5
Bristol-myers squibb company
15
Caribou biosciences inc
7
Cellectis s.a.
13
Citius pharmaceuticals, inc.
11
Corvus pharmaceuticals, inc.
7
Coya therapeutics, inc.
6
Crispr therapeutics ag
4
Cytomed therapeutics pte. ltd.
4
Cytomx therapeutics, inc.
4
Eli lilly and company
15
Enlivex therapeutics ltd.
4
Equillium, inc.
5
Fate therapeutics, inc.
12
Fortress biotech, inc.
19
Gilead sciences, inc.
34
Glaxosmithkline plc
4
Gracell biotechnologies inc - adr
5
Harpoon therapeutics, inc.
8
Igm biosciences, inc.
6
Immix biopharma, inc.
7
Immune therapeutics, inc.
7
Immunitybio inc
6
In8bio inc
14
Incyte corporation
14
Intellia therapeutics, inc.
4
Johnson & johnson
18
Kiromic biopharma, inc.
8
Kymera therapeutics, inc.
4
Lava therapeutics nv
5
Marker therapeutics, inc.
10
Morphosys ag
4
Mustang bio, inc.
21
Nektar therapeutics
8
Novartis ag
17
Oncternal therapeutics, inc.
5
Orange
12
Phio pharmaceuticals corp.
6
Poseida therapeutics, inc.
18
Precision biosciences, inc.
10
Regen biopharma inc
6
Sana biotechnology inc
8
Sanofi
16
Sellas life sciences group, inc.
5
Soligenix, inc.
15
Tonix pharmaceuticals holding corp.
5
Viracta therapeutics inc
5
Xencor, inc.
8
Symbols
AMGN
1
ATNX
1
BLCM
1
BMY
1
CABA
1
DTIL
10
GILD
1
INCY
1
NVS
1
NVSEF
1
PSTX
1
SNY
1
SNYNF
1
TGTX
1
Exchanges
Nasdaq
10
Nyse
1
Crawled Date
2024 - 01 - 09
1
2022 - 11 - 28
1
2022 - 11 - 03
1
2022 - 08 - 12
1
2022 - 01 - 07
1
2021 - 11 - 09
1
2021 - 07 - 01
1
2021 - 01 - 25
1
2021 - 01 - 19
1
2020 - 12 - 04
1
Crawled Time
12:00
2
12:01
1
12:03
1
14:00
1
14:15
1
14:20
1
15:00
1
18:00
1
19:00
1
Source
www.biospace.com
4
www.globenewswire.com
3
www.precisionbiosciences.com
2
www.prnewswire.com
1
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
t-cell
entities :
Precision biosciences, inc.
save search
TG Therapeutics Announces Global License Agreement with Precision BioSciences for the Development and Commercialization of Precision’s Allogeneic CD19 CAR T Cell Therapy Program for the Treatment of Autoimmune Diseases
Published:
2024-01-09
(Crawled : 12:00)
- globenewswire.com
TGTX
|
$14.25
1.06%
1.05%
3.2M
|
Health Technology
|
-33.1%
|
O:
-8.22%
H:
9.05%
C:
7.47%
DTIL
|
$10.33
6.72%
6.29%
31K
|
Health Technology
|
2470.35%
|
O:
10.0%
H:
14.23%
C:
0.09%
cd19
license
cell
treatment
global
commercialization
program
therapeutics
agreement
therapy
Effective Cell Dose and Functional Attributes of Azercabtagene Zapreleucel (azer-cel; PBCAR0191) Associate with Allogeneic CAR T-Cell Safety and Efficacy in Patients with Relapsed/Refractory B-Cell Lymphoma
Published:
2022-11-28
(Crawled : 18:00)
- precisionbiosciences.com
DTIL
|
$10.33
6.72%
6.29%
31K
|
Health Technology
|
630.71%
|
O:
-0.71%
H:
2.88%
C:
-2.88%
INCY
|
$51.62
-0.58%
-0.58%
2.5M
|
Health Technology
|
-34.0%
|
O:
0.05%
H:
0.89%
C:
-0.6%
pbcar0191
t-cell
Precision BioSciences Announces Data Presentation on Effective Cell Dose and Functional Attributes of CD19 Allogeneic CAR T, Azer-Cel, at the Upcoming 2022 American Society of Hematology (ASH) Annual Meeting
Published:
2022-11-03
(Crawled : 14:00)
- biospace.com/
DTIL
|
$10.33
6.72%
6.29%
31K
|
Health Technology
|
635.97%
|
O:
-2.88%
H:
3.7%
C:
3.7%
cd19
meeting
presentation
Global Engineered T Cells Market Report 2022-2027: Immuno-Oncology Sector Increasing R&D Funding & Expanding Gene Therapy Marketspace Generating High-Potential Opportunities
Published:
2022-08-12
(Crawled : 14:20)
- prnewswire.com
NVSEF
|
News
|
$95.11
6.88%
490
|
Health Technology
|
37.56%
|
O:
1.51%
H:
0.0%
C:
0.0%
NVS
|
News
|
$97.28
2.27%
0.31%
3.7M
|
Health Technology
|
13.67%
|
O:
-0.61%
H:
0.9%
C:
0.73%
BMY
|
$48.99
-0.31%
0.0%
9.1M
|
Health Technology
|
-34.21%
|
O:
0.16%
H:
1.53%
C:
1.33%
DTIL
|
$10.33
6.72%
6.29%
31K
|
Health Technology
|
527.61%
|
O:
0.61%
H:
23.78%
C:
22.56%
PSTX
|
$2.15
-0.23%
-0.23%
420K
|
Health Technology
|
-47.45%
|
O:
-1.7%
H:
12.62%
C:
8.91%
GILD
|
$67.03
0.12%
0.12%
5.2M
|
Health Technology
|
7.33%
|
O:
0.42%
H:
0.45%
C:
0.4%
CABA
|
$13.31
-0.08%
-0.08%
760K
|
Health Technology
|
818.62%
|
O:
2.76%
H:
4.7%
C:
2.68%
BLCM
|
$0.0748
381.28%
6.1K
|
Health Technology
|
-94.73%
|
O:
3.58%
H:
1.99%
C:
-1.41%
ATNX
|
$0.2031
-7.78%
1.9M
|
Health Technology
|
-62.24%
|
O:
2.25%
H:
0.0%
C:
0.0%
AMGN
|
News
|
$273.69
0.66%
0.65%
2.5M
|
Health Technology
|
10.14%
|
O:
0.07%
H:
0.54%
C:
-0.05%
global
report
funding
therapy
market
Allogeneic CAR-T PBCAR0191 with Intensified Lymphodepletion is Highly Active in Subjects with Relapsed/Refractory B-Cell Malignancies
Published:
2022-01-07
(Crawled : 19:00)
- precisionbiosciences.com
SNYNF
|
News
|
$92.7
-2.18%
600K
|
Health Technology
|
Email alert
Add to watchlist
SNY
|
News
|
$47.69
1.15%
1.13%
1.7M
|
Health Technology
|
Email alert
Add to watchlist
DTIL
|
$10.33
6.72%
6.29%
31K
|
Health Technology
|
Email alert
Add to watchlist
pbcar0191
car-t
cel
t-cell
Precision BioSciences to Highlight Capabilities of ARCUS Gene Editing for Allogeneic CAR T Cell Immunotherapies at The Society for Immunotherapy of Cancer 36th Annual Meeting
Published:
2021-11-09
(Crawled : 14:15)
- biospace.com/
DTIL
|
$10.33
6.72%
6.29%
31K
|
Health Technology
|
4.39%
|
O:
-2.04%
H:
0.0%
C:
0.0%
immunotherapy
therapy
cancer
arcus
car-t
t-cell
Precision BioSciences Doses First Patient in Phase 1 Allogeneic CAR T Clinical Trial of PBCAR19B Immune Evading Stealth Cell for Relapsed/Refractory Non-Hodgkin Lymphoma
Published:
2021-07-01
(Crawled : 12:00)
- biospace.com/
DTIL
|
$10.33
6.72%
6.29%
31K
|
Health Technology
|
-18.29%
|
O:
1.04%
H:
1.74%
C:
0.08%
phase 1
trial
car-t
Precision BioSciences Receives Notice of Allowance for U.S. Patent Application Covering PBCAR19B, a Stealth Cell, CD19 Allogeneic CAR T Candidate for Non-Hodgkin Lymphoma
Published:
2021-01-25
(Crawled : 12:01)
- globenewswire.com
DTIL
|
$10.33
6.72%
6.29%
31K
|
Health Technology
|
-23.02%
|
O:
5.49%
H:
0.07%
C:
-5.21%
patent
car-t
application
Precision BioSciences Announces FDA Accepts IND for PBCAR19B, a Next-Generation, Stealth Cell, CD19 Allogeneic CAR T Candidate for Non-Hodgkin Lymphoma
Published:
2021-01-19
(Crawled : 12:03)
- globenewswire.com
DTIL
|
$10.33
6.72%
6.29%
31K
|
Health Technology
|
-9.47%
|
O:
9.91%
H:
18.6%
C:
17.87%
fda
fda acceptance
car-t
Precision BioSciences Reports Positive Interim Results from PBCAR0191 Phase 1/2a Trial in Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) and R/R B-cell Acute Lymphoblastic Leukemia (B-ALL)
Published:
2020-12-04
(Crawled : 15:00)
- biospace.com/
DTIL
|
$10.33
6.72%
6.29%
31K
|
Health Technology
|
0.0%
|
O:
-4.69%
H:
2.36%
C:
-14.82%
positive
results
leukemia
trial
phase 3
phase 1
phase 2
t-cell
Gainers vs Losers
78%
22%
Top 10 Gainers
MTTR
|
News
4
|
$4.6
164.37%
62.17%
28M
|
AGBA
|
$2.94
135.2%
57.48%
66M
|
Finance
EDBL
|
News
|
$6.46
71.81%
41.8%
2M
|
MTC
|
$2.25
44.23%
30.67%
6M
|
Technology Services
OPRT
|
News
|
$3.175
41.11%
29.13%
12M
|
Finance
SHIM
|
$3.05
35.56%
26.23%
1.1M
|
HKIT
|
$1.345
31.86%
24.16%
390K
|
Technology Services
ABVC
|
$1.36
30.77%
23.53%
7.4M
|
Wholesale Trade
OST
|
$0.512
28.0%
21.88%
290K
|
POET
|
$1.59
27.2%
21.38%
4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.